We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App




Test Predicts Death in Patients with Serious Liver Disease

By LabMedica International staff writers
Posted on 12 Apr 2016
Acute-on-chronic liver failure (ACLF) is a sudden deterioration of the liver function in a patient with liver cirrhosis accompanied by failure of one or more organ systems and this liver disease has a serious prognosis and the four-week mortality rate is 20% to 30%.

This condition is often triggered by an infection, bleeding or other stressful events and due to the severity of the disease it is important to develop a test to identify patients with the highest risk of developing this condition and thus the highest risk of a fatal outcome.

Scientists at Aarhus University (Denmark) screened patients at liver units in 29 university hospitals with a diagnosis of cirrhosis based on previous liver biopsy findings or a composite of clinical signs and findings provided by laboratory test results, endoscopy, and radiologic imaging. Eighty-six cirrhosis patients had no ascites and no ACLF, 580 had ascites but no ACLF; 100, 66, and 19 had ACLF-grade-I (ACLF-I), ACLF-II, and ACLF-III, respectively.

The scientists measured the circulating macrophage activation markers soluble sCD163 and mannose receptor (sMR) and related them to the short-(one to three months) and long-term (6 months) mortality in the cirrhosis patients. The plasma concentration of sCD163 was determined in duplicate in samples that had been frozen at -80 °C by an in-house sandwich enzyme-linked immunosorbent assay (ELISA) using a BEP-2000 ELISA-analyzer (Dade Behring, Deerfield, IL, USA). The team measured sMR by a newly developed in-house ELISA assay.

The investigators found a stepwise increase in median sCD163: 5.68; 8.26; 9.50; 15.68; 20.18 mg/L, and sMR: 0.60; 0.81; 1.17; 1.41mg/L with increasing grades of ACLF. Both sCD163 and sMR were independently associated with short and long-term mortality and showed equal or higher predictive accuracy than MELD, CLIF-C ACLF and CLIF-C AD scores. Addition of the macrophage markers to the clinical scores improved the prognostic efficacy. In ACLF patients sCD163 improved prediction of short-term mortality and in patients without ACLF sMR improved prediction of long-term mortality.

The authors concluded that the severity related increase in sCD163 and sMR and close association with mortality suggest a primary importance of inflammatory activation of liver macrophages in the emergence and course of ACLF. The study was published in the April 2016 issue of the Journal of Hepatology.

Related Links:

Aarhus University
Dade Behring



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.